NCT00852137View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Actinic Keratosis
Interventions
DRUG

PEP005 (ingenol mebutate) Gel, 0.05%

PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days

DRUG

Vehicle Gel

Vehicle Gel once daily for 2 consecutive days

Trial Locations (1)

78759

DermResearch, Inc., Austin

Sponsors

Lead Sponsor

Peplin
All Listed Sponsors
lead

Peplin

INDUSTRY

NCT00852137 - A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis | Biotech Hunter | Biotech Hunter